Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Recurrent bilateral brachial plexus neuritis following rapid semaglutide-induced weight loss: a case report.

Lesinszki LS, Khalili R, Jiang H, Jha S, Bernad PG

BMC neurology26 Jan 2026Cited by 1 (Europe PMC)

PMID41588354 (opens in a new tab)PMCIDPMC12918017 (opens in a new tab)DOI10.1186/s12883-026-04664-4 (opens in a new tab)PepBankPUB-41588354
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BACKGROUND: Brachial plexus neuritis, or Parsonage–Turner syndrome, is an uncommon neuropathy marked by acute pain followed by weakness, often triggered by infection, vaccination, trauma, or metabolic stress but the exact cause of this disease remained unknown. Semaglutide is widely used for the treatment of type 2 diabetes and obesity. With its increasing use, there have been reports suggesting a possible association with neuropathies. Currently, there is no information suggesting a possible association between the use of semaglutide and brachial plexus neuritis. CASE PRESENTATION: A 39-year-old man with a prior episode of unilateral brachial neuritis developed recurrent bilateral upper limb weakness after an eight-month, 70-pound semaglutide-associated weight loss. He presented with bilateral radial sensory loss, finger extensor paralysis, right triceps weakness and decreased grip strength on the left side. Corticosteroids provided pain relief, but motor and sensory deficits persisted despite physiotherapy. CONCLUSION: This case highlights a temporal association between rapid pharmacologic weight loss and recurrent idiopathic brachial plexus neuritis, emphasizing the importance of gradual, nutritionally supported weight reduction and vigilance for neuromuscular complications during GLP-1 receptor agonist therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 39-year-old man with a prior unilateral brachial neuritis, recurrent bilateral upper limb weakness developed after eight months of semaglutide-associated weight loss.

    In plain wordsIn one man, upper limb weakness from nerve inflammation returned in both arms after months of semaglutide-linked weight loss. One case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableRecurrent bilateral brachial plexus neuritis
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · eight monthsAs given in this study (human).

    Source sentences

    Summary
    CASE PRESENTATION: A 39-year-old man with a prior episode of unilateral brachial neuritis developed recurrent bilateral upper limb weakness after an eight-month, 70-pound semaglutide-associated weight loss.
    1 context sentence
    Summary · context
    He presented with bilateral radial sensory loss, finger extensor paralysis, right triceps weakness and decreased grip strength on the left side.
  2. 02HumanCase report or seriesEfficacy outcome

    A 39-year-old man lost 70 pounds over eight months of semaglutide-associated weight loss.

    In plain wordsOne man lost 70 pounds over eight months of semaglutide-associated weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss during semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · eight monthsAs given in this study (human).

    Measurements

    Weight loss
    70 pounds
    case patient

    Source sentences

    Summary
    an eight-month, 70-pound semaglutide-associated weight loss

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.